Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3848575 · 2 trials · 3 indications
A summary of TEAEs, SAEs and Other Non-serious Adverse Events (AEs), Regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3848575 Dose 1 | EXPERIMENTAL | LY3848575 low dose administered subcutaneously (SC). |
| LY3848575 Dose 2 | EXPERIMENTAL | LY3848575 mid dose administered SC. |
| LY3848575 Dose 3 | EXPERIMENTAL | LY3848575 high dose administered SC. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered SC. |
| LY3848575 IV | EXPERIMENTAL | Single ascending doses of LY3848575 administered intravenously (IV). |
| Placebo IV | PLACEBO_COMPARATOR | Placebo administered IV. |
| LY3848575 SC | EXPERIMENTAL | Multiple doses of LY3848575 administered subcutaneously (SC). |
| Placebo SC | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3848575 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a Visual Analog Scale (VAS) pain value ≥40 and \<95 at screening. * Presence of painful distal sensory polyneuropathy (DSP) without prominent motor or autonomic features with gradual or insidious onset with a minimum duration of 6 months and a known cause of nerve injury,...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE2 | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA |
| Dogwood Therapeutics Inc | DWTX | 1 | PHASE2 | Halneuron |
| Sangamo Therapeutics, Inc. | SGMO | 1 | PHASE1 | ST-503 |
| Boston Scientific Corporation | BSX | 1 | N/A | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | N/A | Undisclosed |
LY3848575 is an investigational small molecule being studied for neuropathic pain, specifically painful distal sensory polyneuropathy. It has also been evaluated in healthy participants. The drug is being developed by Eli Lilly and Company and is currently in clinical development.
LY3848575 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is an investigational small molecule in clinical development for neuropathic pain.
LY3848575 is in clinical development. A Phase 1 study in healthy participants has been completed, and a Phase 2 study in participants with painful distal sensory polyneuropathy has also been completed. The drug is investigational and not yet approved.
LY3848575 has been studied in two completed clinical trials. NCT05727072 was a Phase 1 study in healthy participants in the United States. NCT06568042 was a Phase 2 study comparing LY3848575 to placebo in participants with painful distal sensory polyneuropathy, conducted across multiple countries.
Yes, LY3848575 has been studied in a placebo-controlled trial. The Phase 2 study NCT06568042 compared LY3848575 against placebo in participants with painful distal sensory polyneuropathy. This trial was randomized and double-blind, with 558 participants enrolled.